On May 20, 2025, Haemonetics (HAE, Financial) received a reaffirmation from JMP Securities, maintaining the stock's current standing with a "Market Outperform" rating. The consistency in the rating reflects a stable outlook for the company's stock performance.
JMP Securities analyst, David Turkaly, reiterated the price target for Haemonetics (HAE, Financial) at $100.00 USD. This target remains unchanged from the previous assessment, indicating steady expectations for HAE's market value.
Haemonetics (HAE, Financial) has consistently been under observation by JMP Securities, and the unchanged price target suggests confidence in the company's capabilities and market position. The reiterated "Market Outperform" rating underscores the analyst's perspective that the stock is expected to perform better than the overall market.
This reaffirmation comes as Haemonetics (HAE, Financial) continues to operate on the New York Stock Exchange. The unchanged price targets and ratings are crucial indicators for investors considering this stock for their portfolios.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Haemonetics Corp (HAE, Financial) is $91.78 with a high estimate of $108.00 and a low estimate of $68.00. The average target implies an upside of 32.32% from the current price of $69.36. More detailed estimate data can be found on the Haemonetics Corp (HAE) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Haemonetics Corp's (HAE, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Haemonetics Corp (HAE, Financial) in one year is $93.35, suggesting a upside of 34.59% from the current price of $69.36. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Haemonetics Corp (HAE) Summary page.
